Lumateperone
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 146 publications
Evaluation of Sexual Function With Adjunctive Lumateperone in Patients With Major Depressive Disorder.
Journal: The Journal of clinical psychiatry
Published: September 03, 2026
Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project.
Journal: BMJ (Clinical research ed.)
Published: August 11, 2026
Systematic review and network meta-analysis of the efficacy, safety and tolerability of xanomeline plus trospium chloride compared with eight oral antipsychotics for the acute treatment of schizophrenia.
Journal: Journal of comparative effectiveness research
Published: July 30, 2026
A high-throughput LC-MS/MS method for simultaneous determination of lumateperone and its four metabolites in human plasma: application to a clinical trial.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: July 15, 2026
MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.
Journal: Physical chemistry chemical physics : PCCP
Published: June 16, 2026
Long-term safety and tolerability of lumateperone 42 mg in patients with stable symptoms of schizophrenia: Results from a 1-year open-label study.
Journal: Schizophrenia research
Published: April 16, 2026
A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.
Journal: Clinical neuropharmacology
Published: April 08, 2026
Lumateperone as an alternative to clozapine in treatment-resistant schizophrenia: Insights from a quantitative systems pharmacology model.
Journal: The Journal of pharmacology and experimental therapeutics
Published: March 31, 2026
Safety and Tolerability of Adjunctive Lumateperone for the Treatment of Major Depressive Disorder: A Pooled Analysis of Two Randomized Placebo-Controlled Trials.
Journal: CNS drugs
Published: March 13, 2026
Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis.
Journal: Advances in therapy
Published: February 27, 2026
Addendum: Urinary incontinence with second-generation antipsychotic drugs.
Journal: The Medical letter on drugs and therapeutics
Published: February 23, 2026
Last Updated: 09/26/2026